A DNA methylation marker test performed on urine samples obtained from patients with non-muscle-invasive bladder cancer (NMIBC) has the ability to predict tumor recurrence with both high sensitivity and specificity. The urine test, which measures three distinct DNA methylation markers, detected tumor recurrence with both high sensitivity and specificity (80% sensitivity and 97% specificity) in NMIBC patients.
Hey, check out all the engineering jobs. Post your resume today!
